CEL-SCI Stock Price, News & Analysis (NYSEAMERICAN:CVM)

$2.20 0.24 (12.24 %)
(As of 01/22/2018 04:00 PM ET)
Previous Close$1.96
Today's Range$1.98 - $2.20
52-Week Range$1.46 - $4.00
Volume263,247 shs
Average Volume294,350 shs
Market Capitalization$23.19 million
P/E Ratio-1.36
Dividend YieldN/A
Beta-1.6

About CEL-SCI (NYSEAMERICAN:CVM)

CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus and human papillomavirus co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis.

Receive CVM News and Ratings via Email

Sign-up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNYSEAMERICAN:CVM
CUSIPN/A
Phone+1-703-5069460

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-1.35802469135802
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($1.62)
Net IncomeN/A
Net Margins-25,670.27%
Return on EquityN/A
Return on Assets-81.57%

Miscellaneous

EmployeesN/A
Outstanding Shares13,920,000

CEL-SCI (NYSEAMERICAN:CVM) Frequently Asked Questions

What is CEL-SCI's stock symbol?

CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSEAMERICAN:CVM) posted its quarterly earnings results on Friday, December, 29th. The company reported ($0.58) earnings per share (EPS) for the quarter. View CEL-SCI's Earnings History.

Are investors shorting CEL-SCI?

CEL-SCI saw a decrease in short interest during the month of December. As of December 29th, there was short interest totalling 510,101 shares, a decrease of 3.2% from the December 15th total of 526,760 shares. Based on an average trading volume of 161,531 shares, the days-to-cover ratio is presently 3.2 days. Approximately 4.6% of the company's stock are short sold.

Who are some of CEL-SCI's key competitors?

Who are CEL-SCI's key executives?

CEL-SCI's management team includes the folowing people:

  • Geert R. Kersten Esq., Chief Executive Officer, Treasurer, Director (Age 56)
  • Patricia B Prichep, Senior Vice President - Operations, Corporate Secretary (Age 63)
  • John Cipriano, Senior Vice President - Regulatory Affairs (Age 72)
  • Daniel H Zimmerman Ph.D., Senior Vice President - Research, Cellular Immunology (Age 73)
  • Eyal Talor Ph.D., Chief Scientific Officer (Age 58)
  • Robert E. Watson, Director (Age 59)
  • Alexander G. Esterhazy, Independent Director (Age 73)
  • Peter R. Young Ph.D., Independent Director (Age 70)

How do I buy CEL-SCI stock?

Shares of CEL-SCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CEL-SCI's stock price today?

One share of CEL-SCI stock can currently be purchased for approximately $2.20.

How big of a company is CEL-SCI?

CEL-SCI has a market capitalization of $23.19 million.

How can I contact CEL-SCI?

CEL-SCI's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at +1-703-5069460.


MarketBeat Community Rating for CEL-SCI (CVM)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  53 (Vote Underperform)
Total Votes:  103
MarketBeat's community ratings are surveys of what our community members think about CEL-SCI and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CEL-SCI (NYSEAMERICAN:CVM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldN/A
Consensus Rating Score: 2.002.002.00N/A
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

CEL-SCI (NYSEAMERICAN:CVM) Consensus Price Target History

Price Target History for CEL-SCI (NYSEAMERICAN:CVM)

CEL-SCI (NYSEAMERICAN:CVM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
10/16/2017Dawson JamesReiterated RatingNeutralView Rating Details
(Data available from 1/22/2016 forward)

Earnings

CEL-SCI (NYSEAMERICAN:CVM) Earnings History and Estimates Chart

Earnings by Quarter for CEL-SCI (NYSEAMERICAN:CVM)

CEL-SCI (NYSEAMERICAN CVM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/29/2017Q4 2017($0.58)ViewN/AView Earnings Details
8/9/2017Q3 2017($0.53)ViewN/AView Earnings Details
5/10/2017Q2 2017($0.05)$0.02 millionViewN/AView Earnings Details
2/9/2017Q116$0.01$0.01 millionViewN/AView Earnings Details
12/14/2016Q4 2016($0.25)ViewN/AView Earnings Details
8/10/2016Q316($0.03)$0.13 millionViewN/AView Earnings Details
5/10/2016Q2($0.07)$0.03 millionViewN/AView Earnings Details
2/9/2016Q1 2016$0.50ViewN/AView Earnings Details
12/11/2015Q4 2015($2.50)ViewN/AView Earnings Details
8/7/2015Q3 2015($1.50)ViewN/AView Earnings Details
5/8/2015Q2 2015($0.12)($0.17)$0.10 million$0.20 millionViewN/AView Earnings Details
2/6/2015Q1 2015($0.09)($0.11)$0.07 million$0.14 millionViewN/AView Earnings Details
12/23/2014Q4 2014($2.25)($2.75)ViewN/AView Earnings Details
8/8/2014Q3 2014($2.75)ViewN/AView Earnings Details
5/13/2014Q114($0.11)($0.24)$0.02 million$0.07 millionViewN/AView Earnings Details
2/11/2014Q413($0.11)($0.15)$510.39 millionViewN/AView Earnings Details
1/2/2014Q3($0.27)ViewN/AView Earnings Details
8/9/2013Q3 2013($5.00)($5.00)ViewN/AView Earnings Details
5/14/2013Q213($0.01)$0.07 millionViewN/AView Earnings Details
2/8/2013Q1 2013($0.01)ViewN/AView Earnings Details
12/14/2012Q4 2012($5.00)($5.00)ViewN/AView Earnings Details
8/9/2012Q3 2012($3.00)ViewN/AView Earnings Details
5/10/2012Q2 2012($10.25)ViewN/AView Earnings Details
2/9/2012Q1 2012($4.50)ViewN/AView Earnings Details
12/23/2011Q4 2011($3.25)ViewN/AView Earnings Details
8/9/2011Q3 2011($6.25)ViewN/AView Earnings Details
5/16/2011Q2 2011($9.25)ViewN/AView Earnings Details
2/10/2011Q1 2011($7.50)ViewN/AView Earnings Details
12/13/2010Q4 2010($7.50)ViewN/AView Earnings Details
8/16/2010Q3 2010($2.50)ViewN/AView Earnings Details
5/17/2010Q2 2010($7.00)ViewN/AView Earnings Details
2/16/2010Q1 2010$5.00ViewN/AView Earnings Details
1/13/2010Q4 2009($58.50)ViewN/AView Earnings Details
8/14/2009Q3 2009($12.75)ViewN/AView Earnings Details
5/15/2009Q2 2009($4.00)ViewN/AView Earnings Details
8/19/2008Q3 2008$5.00ViewN/AView Earnings Details
5/16/2008Q2 2008($7.75)ViewN/AView Earnings Details
2/14/2008Q1 2008($5.00)ViewN/AView Earnings Details
1/14/2008Q4 2007($2.50)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

CEL-SCI (NYSEAMERICAN:CVM) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for CEL-SCI (NYSEAMERICAN:CVM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

CEL-SCI (NYSEAMERICAN CVM) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for CEL-SCI (NYSEAMERICAN:CVM)

CEL-SCI (NYSEAMERICAN CVM) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/22/2018Eyal TalorInsiderSell8,192$2.06$16,875.52117,698View SEC Filing  
1/16/2018Eyal TalorInsiderSell1,808$2.15$3,887.20121,156View SEC Filing  
1/12/2018Eyal TalorInsiderSell101$2.15$217.15121,156View SEC Filing  
10/17/2017Vicente Benjamin AsuncionDirectorSell160,000$0.39$62,400.00
8/25/2017Eyal TalorInsiderSell769$1.91$1,468.79118,543View SEC Filing  
8/16/2017Eyal TalorInsiderSell14,019$2.61$36,589.59131,312View SEC Filing  
10/13/2014Geert R KerstenCEOBuy14,999$0.77$11,549.23View SEC Filing  
12/30/2013Geert R KerstenCEOBuy300,000$0.60$180,000.00View SEC Filing  
10/9/2013Geert R KerstenInsiderBuy8,400$0.79$6,636.00View SEC Filing  
6/19/2013Peter R YoungDirectorBuy25,000$0.24$6,000.00View SEC Filing  
6/14/2013Geert R KerstenInsiderBuy145,120$0.24$34,828.80View SEC Filing  
5/20/2013Geert R KerstenCEOBuy40,000$0.25$10,000.00View SEC Filing  
5/2/2013Geert R KerstenCEOBuy118,700$0.27$32,049.00View SEC Filing  
3/27/2013Peter R YoungDirectorBuy25,000$0.23$5,750.00View SEC Filing  
3/26/2013Geert R KerstenCEOBuy348,125$0.21$73,106.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CEL-SCI (NYSEAMERICAN CVM) News Headlines

Source:
DateHeadline
CEL-SCI Co. (CVM) Insider Sells $16,875.52 in StockCEL-SCI Co. (CVM) Insider Sells $16,875.52 in Stock
www.americanbankingnews.com - January 22 at 7:04 PM
Active-Investors: Wired News - Pluristems PLX Cells Demonstrated Inhibition of Cancer Cell Growth in Peer-Reviewed ArticleActive-Investors: Wired News - Pluristem's PLX Cells Demonstrated Inhibition of Cancer Cell Growth in Peer-Reviewed Article
www.finanznachrichten.de - January 17 at 8:27 AM
Wired News – Pluristem’s PLX Cells Demonstrated Inhibition of Cancer Cell Growth in Peer-Reviewed ArticleWired News – Pluristem’s PLX Cells Demonstrated Inhibition of Cancer Cell Growth in Peer-Reviewed Article
finance.yahoo.com - January 17 at 8:26 AM
CEL-SCI Co. (CVM) Sees Significant Decrease in Short InterestCEL-SCI Co. (CVM) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - January 11 at 2:36 AM
CEL-SCI Awarded Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis - Business Wire (press release)CEL-SCI Awarded Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis - Business Wire (press release)
www.businesswire.com - January 8 at 11:51 AM
CEL-SCI Awarded Patent for LEAPS Vaccine in Treatment of Rheumatoid ArthritisCEL-SCI Awarded Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis
finance.yahoo.com - January 8 at 9:50 AM
CEL-SCI Issues Letter to Shareholders - Business Wire (press release)CEL-SCI Issues Letter to Shareholders - Business Wire (press release)
www.businesswire.com - January 4 at 8:47 AM
CEL-SCI Issues Letter to ShareholdersCEL-SCI Issues Letter to Shareholders
finance.yahoo.com - January 3 at 8:46 AM
CEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate DevelopmentsCEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate Developments
finance.yahoo.com - December 29 at 5:09 PM
What Is The Future Prospect For Healthcare And CEL-SCI Corporation (NYSEMKT:CVM)?What Is The Future Prospect For Healthcare And CEL-SCI Corporation (NYSEMKT:CVM)?
finance.yahoo.com - December 29 at 10:08 AM
CEL-SCI Co. (CVM) Short Interest UpdateCEL-SCI Co. (CVM) Short Interest Update
www.americanbankingnews.com - December 27 at 7:24 PM
What Did CEL-SCI Corporation’s (NYSEMKT:CVM) CEO Take Home Last Year?What Did CEL-SCI Corporation’s (NYSEMKT:CVM) CEO Take Home Last Year?
finance.yahoo.com - December 21 at 8:45 AM
CEL-SCI Corp (CVM) Appoints Robert Watson to Board - StreetInsider.comCEL-SCI Corp (CVM) Appoints Robert Watson to Board - StreetInsider.com
www.streetinsider.com - December 19 at 5:13 PM
CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study - Business Wire (press release)CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study - Business Wire (press release)
www.businesswire.com - December 12 at 10:02 AM
Short Interest in CEL-SCI Co. (CVM) Drops By 11.8%Short Interest in CEL-SCI Co. (CVM) Drops By 11.8%
www.americanbankingnews.com - December 12 at 2:26 AM
CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer StudyCEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study
finance.yahoo.com - December 11 at 5:26 PM
CEL-SCI Reports Recent Data Review By the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head ... - Business Wire (press release)CEL-SCI Reports Recent Data Review By the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head ... - Business Wire (press release)
www.businesswire.com - December 9 at 8:44 AM
CEL-SCI Corp (CVM) Reports Data Review By IDMC for Its Pivotal Phase 3 Head and Neck Cancer Study - StreetInsider.comCEL-SCI Corp (CVM) Reports Data Review By IDMC for Its Pivotal Phase 3 Head and Neck Cancer Study - StreetInsider.com
www.streetinsider.com - December 8 at 9:36 AM
CEL-SCI (CVM) Scheduled to Post Quarterly Earnings on TuesdayCEL-SCI (CVM) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - December 5 at 1:44 AM
CEL-SCI Corporation’s (CVM) EPS Grew 65.7% In A Year. Was It Better Than Long-Term Trend?CEL-SCI Corporation’s (CVM) EPS Grew 65.7% In A Year. Was It Better Than Long-Term Trend?
finance.yahoo.com - November 30 at 8:54 AM
Short Interest in CEL-SCI Co. (CVM) Declines By 10.2%Short Interest in CEL-SCI Co. (CVM) Declines By 10.2%
www.americanbankingnews.com - November 27 at 9:56 PM
Flaherty Financial Newsletter Spotlights "CEL-SCI Corporations Global Phase 3 Cancer Immunotherapy Treatment Nearing the Finish Line" in Flaherty Financial Newsletter #60Flaherty Financial Newsletter Spotlights "CEL-SCI Corporation's Global Phase 3 Cancer Immunotherapy Treatment Nearing the Finish Line" in Flaherty Financial Newsletter #60
finance.yahoo.com - November 14 at 6:05 PM
CEL-SCI Announces Update on Arbitration against Former Clinical Research OrganizationCEL-SCI Announces Update on Arbitration against Former Clinical Research Organization
finance.yahoo.com - November 13 at 12:36 PM

SEC Filings

CEL-SCI (NYSEAMERICAN:CVM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CEL-SCI (NYSEAMERICAN:CVM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CEL-SCI (NYSEAMERICAN CVM) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.